"目录号: HY-14149

GPCR/G ProteinNeuronal Signaling-

Cisapride(R 51619)是5-HT4受体激动剂，还是hERG抑制剂。

5-HT Receptor

相关产品

Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Perphenazine-Aripiprazole-Ferulic acid sodium-Olanzapine-Sertindole-

生物活性

Description

Cisapride(R 51619) is a nonselective 5-HT4 receptor agonist, it is also a potent human ether-à-go-go-related gene (hERG) potassium channel inhibitor.IC50 Value: 0.14 μM(EC50 for 5-HT4 receptor) [1]; 9.8 μM (Kv4.3) [2]Target: 5-HT4 Receptorin vitro: Cisapride showed higher inhibitory effects on a hERG current, as indicated by its IC50 of 9.4 × 10-9 M [1]. cisapride on cloned Kv4.3 channels stably expressed in Chinese hamster ovary cells were investigated using the whole-cell patch-clamp technique. Cisapride inhibited Kv4.3 in a concentration-dependent manner with IC50 values of 9.8 uM [2].in vivo: Cisapride (1 mg/kg i.v.), when administered 10 min after the start of GR113808 infusion, did not stimulate either antral or colonic motor activity under treatment with GR113808. The enhanced antral or colonic motor activity induced by these drugs was antagonized by treatment with GR113808 in dogs [3]. cisapride could not bring about more colitis damages through 5HT(4) receptors. Based on the present study further researches are required for investigating the exact roles of 5HT(4) receptors in the pathogenesis of ulcerative colitis[4].Toxicity: cardiac arrythmies

Clinical Trial

NCT01281553

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Gastroesophageal Reflux

September 2003

Phase 4

NCT01281566

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Infant, Premature-Infant, Newborn

March 2003

Phase 4

NCT01286090

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Gastroparesis-Diabetes Mellitus

July 2003

Phase 4

NCT01281540

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Gastroparesis

May 2003

Phase 4

NCT01281553

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Gastroesophageal Reflux

September 2003

Phase 4

NCT01281566

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Infant, Premature-Infant, Newborn

March 2003

Phase 4

NCT01286090

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Gastroparesis-Diabetes Mellitus

July 2003

Phase 4

NCT01281540

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Gastroparesis

May 2003

Phase 4

View MoreCollapse

References

[1].Toga, T., Y. Kohmura, and R. Kawatsu, The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci, 2007. 105(2): p. 207-10.

[2].Sung, K.W. and S.J. Hahn, Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 2013. 386(10): p. 905-16.

[3].Mine, Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther, 1997. 283(3): p. 1000-8.

[4].Motavallian, A, et al., Does Cisapride, as a 5HT(4) Receptor Agonist, Aggravate the Severity of TNBS-Induced Colitis in Rat. Gastroenterol Res Pract, 2012. 2012: p. 362536.